Peptide antagonists of receptor tyrosine kinases, kinase-associated receptors, and other surface proteins Tumor cells express abundant cell surface receptors for growth factors
264 The outcomes of the currently ongoing FLOW study will further inform the therapeutic potential of GLP-1R analogues to improve renal and cardiovascular prognosis in patients with renal impairment and T2D
Rey E, Monier D, Lemonnier MC
The SELECT trial, published in The Lancet (October 22, 2025), provides a landmark analysis confirming that the cardioprotective benefits of semaglutide extend beyond weight loss alone. The SELECT Trial: Study Overview The SELECT trial (NCT03574597) enrolled 17,604 participants aged 45 years and above across 41 countries and 804 sites
This is where it gains its nickname the healing peptide. The precise molecular structure of BPC-157 makes it highly stable and biologically active, with broad impact across muscular, digestive, and hormonal systems
Record the time, date, and any side effects experienced
